

# Journal of Visualized Experiments

## Evaluation method for drug sorption to PVC- and non-PVC-based tubes in administration sets using a pump

--Manuscript Draft--

<b>Manuscript Number:</b>	JoVE55086R3
<b>Full Title:</b>	Evaluation method for drug sorption to PVC- and non-PVC-based tubes in administration sets using a pump
<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Keywords:</b>	drug; sorption; tubes; PVC; non-PVC; administration set
<b>Manuscript Classifications:</b>	92.23: Chemistry and Materials (General); 92.24: Composite Materials; 92.25: Inorganic, Organic and Physical Chemistry; 93.38: Quality Assurance and Reliability
<b>Corresponding Author:</b>	Sung-Joo Hwang Yonsei University College of Pharmacy Yeonsu-gu, Incheon KOREA, REPUBLIC OF
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author E-Mail:</b>	sjh11@yonsei.ac.kr
<b>Corresponding Author's Institution:</b>	Yonsei University College of Pharmacy
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Su-Eon Jin
<b>First Author Secondary Information:</b>	
<b>Other Authors:</b>	Su-Eon Jin
	Siwon You
	Seungho Jeon
	Hyo-Jin Byon
<b>Order of Authors Secondary Information:</b>	
<b>Abstract:</b>	Administration sets are delivery tools for direct application of drugs into the body and are composed of a spike, a drip chamber, tubes, luer adapters (connectors), a needle cover for protection, and other accessories. Drug sorption to tubes of the administration sets is a critical issue in terms of safety and efficacy. Although drug sorption is an important factor in the quality of an administration set, there are no standard evaluation methods for the regulation of drug sorption to the tubes. Here, we describe an evaluation protocol for drug sorption to tubes of administration sets. Tubes made of polyvinyl chloride (PVC)- and non-PVC-based polymeric materials were cut to 1 m in length. Diazepam and tacrolimus were used as model drugs. In the kinetic sorption study, we selected drug concentration and flow rate based on the clinical usage of these drugs. After dilution of each drug in a glass bottle, the diluted drug solution was delivered through tubes of administration sets using a pump. Samples were collected in amber vials at appropriate time points and drugs were analyzed using high-performance liquid chromatography. Drug concentrations and sorption levels to tubes of the administration sets were calculated. Acceptable criteria to ensure the quality of administration sets are recommended.
<b>Author Comments:</b>	Please let me know if you will need anything more to proceed this paper.
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
If this article needs to be "in-press" by a	

certain date, please indicate the date below and explain in your cover letter.

Journal of Visualized Experiments

1 Alewife Center, Suite 200

Cambridge, MA 02140

Tel: 617-945-9051

Fax: 866-381-2236

Jun. 6, 2016

Dear Editor-in-Chief,

Please find enclosed our manuscript entitled “**Evaluation method of drug sorption to PVC- and non-PVC-based tubes in administration sets using a pump**” that we would like to be considered for publication in **Journal of Visualized Experiments**. This paper highlights **a protocol for drug sorption to tubes in administration sets**. The techniques presented in this paper and demonstrated in video format will be highly useful for researchers working in the field of **making standards for evaluation of drug sorption to tubes of administration sets and studying chemical and physical interactions between drugs and polymeric materials used in tubes of administration sets**.

**Dr. Su-Eon Jin, Dr. Seungho Jeon, Prof. Hyo-Jin Byon and Prof. Sung-Joo Hwang** designed the procedures described in the manuscript. **Dr. Su-Eon Jin and Siwon You** performed the experiments and analyzed the data. Finally, **Dr. Su-Eon Jin and Prof. Sung-Joo Hwang (I)** wrote the manuscript.

During the preparation and submission of this manuscript, we have been kindly assisted by **Dr. Benjamin Werth, Science Editor - Chemistry**.

Thank you for your consideration of this manuscript. My address, phone number, fax number, and e-mail address are listed on the manuscript title page and last page of this cover letter. Please let me know if you will need anything more to process this paper. We look forward to hearing from you.

Sincerely yours,

**Sung-Joo Hwang, Ph.D.**

Professor

College of Pharmacy, Yonsei University

85, Songdogwahak-ro, Yeonsu-gu, Incheon, 406-840, Korea

Tel: +82-32-749-4518

Fax: +82-32-749-4105

Email: [sjh11@yonsei.ac.kr](mailto:sjh11@yonsei.ac.kr)

**Suggested Reviewers:**

1. Min-Soo Kim, Ph.D., Assistant Professor, Pusan National University, [minsookim@pusan.ac.kr](mailto:minsookim@pusan.ac.kr)
2. Jong-Hyuk Sung, Ph.D., Assistant Professor, Yonsei University, [brian99@empas.com](mailto:brian99@empas.com)
3. Sitaram Velaga, Ph.D., Professor, Luleå University of Technology, [sitram.velaga@ltu.se](mailto:sitram.velaga@ltu.se)
4. Rodolfo Pinal, Ph.D., Professor, Purdue University, [rpinal@purdue.edu](mailto:rpinal@purdue.edu)
5. Soon-Sun Hong, Ph.D., Professor, Inha University, [hongs@inha.ac.kr](mailto:hongs@inha.ac.kr)
6. Cheong-Weon Cho, Ph.D., Professor, Chungnam National University, [chocw@cnu.ac.kr](mailto:chocw@cnu.ac.kr)

**TITLE:**

Evaluation of drug sorption to PVC- and non-PVC-based tubes in administration sets using a pump

**AUTHORS & AFFILIATIONS:**

Su-Eon Jin<sup>1,2,3</sup>, Siwon You<sup>1,3</sup>, Seungho Jeon<sup>4</sup>, Hyo-Jin Byon<sup>2</sup> and Sung-Joo Hwang<sup>1,3</sup>

<sup>1</sup>College of Pharmacy, Yonsei University, Incheon, 21983, Republic of Korea

<sup>2</sup>College of Medicine, Yonsei University, Seoul, 03722, Republic of Korea

<sup>3</sup>Yonsei Institute of Pharmaceutical Sciences, Incheon, 21983, Republic of Korea

<sup>4</sup>Polysciencetech Co. Ltd, Anseong, Gyeonggi, 17508, Republic of Korea

**EMAIL ADDRESSES:**

Su-Eon Jin (hibis1@gmail.com)

Siwon You (yswrswn@naver.com)

Seungho Jeon (towngroup@daum.net)

Hyo-Jin Byon (jinoben@yuhs.ac)

**CORRESPONDING AUTHOR:**

Prof. Sung-Joo Hwang

College of Pharmacy, Yonsei University

85 Songdogwahak-ro, Yeonsu-gu, Incheon 21983, Republic of Korea

Telephone: +82-32-749-4518; Fax: +82-32-749-4105

E-mail: [sjh11@yonsei.ac.kr](mailto:sjh11@yonsei.ac.kr)

**KEYWORDS:**

Drug, Sorption, Tubes, PVC, Non-PVC, Administration set

**SHORT ABSTRACT:**

We report a method for drug sorption evaluation using a pump and model drugs (diazepam and tacrolimus). After drug analysis using high-performance liquid chromatography, drug concentrations and sorption levels in the tubes of administration sets are calculated.

**LONG ABSTRACT:**

Administration sets are delivery tools for the direct application of drugs into the body and are composed of a spike, a drip chamber, tubes, Luer adapters (connectors), a needle cover for protection, and other accessories. Drug sorption to tubes of administration sets is a critical issue in terms of safety and efficacy. Although drug sorption is an important factor in the quality of an administration set, there are no standard evaluation methods for the regulation of drug sorption to the tubes. Here, we describe an evaluation protocol for drug sorption to tubes of administration sets. Tubes made of polyvinyl chloride (PVC)- and non-PVC-based polymeric materials were cut to 1 m in length. Diazepam and tacrolimus were used as model drugs. In the kinetic sorption study, we selected the drug concentration and flow rate based on the clinical usage of these drugs. After the dilution of each drug in a glass bottle, the diluted drug

solution was delivered through tubes of administration sets using a pump. Samples were collected in amber vials at appropriate time points and the drugs were analyzed using high-performance liquid chromatography. Drug concentrations and sorption levels to tubes of the administration sets were calculated. Acceptable criteria to ensure the quality of administration sets are recommended.

## **INTRODUCTION:**

Administration sets are composed of a spike, a drip chamber, tubes, Luer adapters (connectors), and a needle cover for protection. Other accessories, such as an airway check valve, a regulating clamp, an in-line filter, a Y-tube with cap (an injection port), and a needle, can also be attached to administration sets. Drug sorption to tubes is a critical issue in the delivery of injectable drugs<sup>1</sup>. Sorption describes the adsorption of a drug to the polymer surface and the absorption of a drug into the polymeric matrix<sup>2</sup>. Drug sorption to tubes in administration sets causes unpredictable drug loss and makes it difficult to control the delivered drug concentration. Drug sorption to polymeric tubes is therefore a major impediment to the precise transfer of injectable drugs into the body. However, there are no standard methods or regulatory guidelines for the evaluation of drug sorption to tubes in administration sets.

The levels of drug sorption to tubes in administration sets have been reported using various evaluation methods<sup>1-5</sup>. Test methods and model drugs are key factors in sorption evaluation. The pump method<sup>1, 3</sup> and drip method<sup>4, 5</sup> have been widely used for sorption tests. In general, the pump method should be used in the case of drugs with low concentrations and low flow rates as the infusion conditions. Using various evaluation methods, many studies of drug sorption have been reported for polyvinyl chloride (PVC)- and non-PVC-based tubes in administration sets<sup>1-3, 5</sup>. Many sorptive drugs can be selected to investigate whether the tubes of the administration sets have drug sorption potential or not. Diazepam (Figure 1a)<sup>1, 2</sup>, tacrolimus (Figure 1b)<sup>5</sup>, nitroglycerin<sup>2</sup>, and cyclosporin A<sup>3</sup> are representative drugs with high sorption in PVC- and non-PVC-based tubes.

For the evaluation of drug sorption to the tubes, test conditions such as flow rate and drug concentration are based on the clinical use of the selected drugs<sup>1, 6, 7</sup>. In the case of diazepam, a high concentration of 100 µg/mL was used at a flow rate of 1 mL/min to mimic the initial dose for the treatment of status epilepticus<sup>1</sup>. For tacrolimus, a concentration of 10 µg/mL was delivered at a flow rate of 10 mL/h. Dextrose solution (5%) was used for the dilution of drug injections, and tube length was fixed at 1 m. Glass bottles and vials should be used to prevent additional sorption during the experiment and storage.

In this study, we conducted a kinetic sorption study with the model drugs, diazepam and tacrolimus, using a pump method. Specific details of this protocol, from tube preparation to sorption evaluation, were described previously. Methods for the evaluation of drug sorption have already been used to confirm drug properties for injections and to recommend the clinical use of injections with administration sets on a case-by-case basis<sup>1-7</sup>. This protocol may be used as a standard technique for the sorption evaluation

of administration sets. International standards for the evaluation of drug sorption to tubes may be necessary to ensure the safety and efficacy of drug delivery.

## **PROTOCOL:**

### **1. Preparation of tubes in administration sets**

Note: Precisely perform the cutting step to eliminate the effect of differences in tube length on drug sorption.

1.1) Label the end of the tubes with the tube type (e.g., PVC, polyurethane (PU), and polyolefin (PO)) using a marker.

1.2) Remove all detachable accessories, such as connectors and needle covers.

1.3) Using a sharp razor to ensure clean edges, cut the tubes to 1 m in length from the connection of the drip chamber.

### **2. Dilution of drug injections**

Note: Use a glass bottle (1 L) as the container for the injected drug solution. Perform the dilution step precisely. Verify the composition of the marketed drug product and use the same batch number for a whole experimental set.

2.1) Label bottles with the drug names (e.g., diazepam or tacrolimus).

2.2) Dilute the drug injections with 5% dextrose solution, from 1 mg/mL to 100 µg/mL for diazepam injections (10 mL of diazepam injection in 100 mL of 5% dextrose solution) and from 5 mg/mL to 10 µg/mL for tacrolimus injections (200 µL of tacrolimus injection in 100 mL of 5% dextrose solution).

Note: Set up the tested concentrations of drugs and solvents based on the clinical usage.

2.3) Gently mix the diluted solutions in the bottle by swirling to obtain homogenous drug solutions.

2.4) Collect diluted solutions (1-10 mL) in amber vials using a glass graduated cylinder.

2.5) Verify the concentration, as described in step 4.

Note: Use these concentrations of drugs as concentrations at the starting points.

### **3. Kinetic sorption study using an infusion pump**

Note: Confirm the tube-dependent flow rate using a pump prior to the sorption test due to the hardness of tubes. Collect samples at precise time points and use glass bottles and vials to prevent additional drug sorption during storage. Perform the test as shown

in Figure 2. Protect the drug solution against light if the drug has photosensitivity. Perform the experiments in triplicate.

3.1) Without creating air bubbles, preload a diluted solution of the drug into the tube using a syringe.

3.1.1) Connect one end of the tube to a syringe.

3.1.2) Put the other end of the tube into the bottled drug solution.

3.1.3) Pull back the syringe plunger until the tube is completely filled with the drug solution.

3.2) Install the tube into an infusion pump.

3.2.1) Open the door of the infusion pump and push the release lever.

3.2.2) Insert the preloaded tube into the infusion pump and keep it straight.

3.2.3) Remove the syringe at the end of the tube after installation.

3.2.4) Put the end of tube into a chemically resistant borosilicate glass graduated cylinder to collect the drug solution after it passes through the tube.

3.3) Set the flow rate based on the type of tube in the administration set (PVC, PU, or PO) and the drug (e.g., 1 mL/min for diazepam and 10 mL/h for tacrolimus).

3.4) Collect samples into amber vials at various time points, at room temperature.

3.4.1) Collect 1-mL diazepam samples at 0.05, 0.30, 0.55, and 1.05 h.

3.4.2) Collect 10-mL tacrolimus samples at 1.05, 2.05, 3.05, and 4.05 h.

#### **4. Analysis of drug using high-performance liquid chromatography (HPLC)**

Note: Recommended HPLC methods for drug analysis are described in references <sup>1, 8, 9</sup>. Use tandem mass spectrometry (MS/MS) and immunoassay after sample preparation as alternative methods<sup>10, 11</sup>. Perform the experiments in triplicate.

4.1) Weigh the drugs and dissolve them in organic solvents at a concentration of 1 mg/mL as stock solutions.

4.1.1) Use methanol as a solvent for diazepam stock solution due to the low solubility of diazepam in 5% dextrose.

4.1.2) Use acetonitrile as a solvent for tacrolimus stock solution due to the low solubility of tacrolimus in 5% dextrose.

4.2) Prepare standard solutions by diluting the stock solutions.



4.2.1) Dilute diazepam stock solutions with methanol to 0.3125, 0.625, 1.25, 2.5, 5.0, 10.0, and 20.0 µg/mL.

4.2.2) Dilute tacrolimus stock solutions with 5% dextrose to 2.5, 5.0, 10.0, 15.0, and 20.0 µg/mL.

#### 4.3) Analyze standards using the HPLC method with UV detection<sup>1, 8, 9</sup>.

Note: Use an appropriate detection method (UV, fluorescence, etc.) for drug analysis.

4.3.1) Inject 10 µL of standards into an HPLC system with UV detection equipped with a C<sub>18</sub> column (1.5 mm × 250 mm, 5 µm). See Table 1 for analysis conditions.

4.3.2) Confirm the specificity and linearity<sup>1, 8, 9</sup>.

4.3.2.1) For specificity, monitor the drug peak (*i.e.*, whether it was separated from other peaks in the chromatogram) to identify the drug.

4.3.2.2) Confirm linearity at the calibration range (*i.e.*, whether the peak area results are directly proportional to the concentrations).

#### 4.3.3) Obtain calibration curves.

4.3.3.1) Create graphs based on concentration versus peak area value from chromatograms of the standards<sup>1, 8, 9</sup>.

4.3.3.2) Obtain linear regression equations with R<sup>2</sup> for the calibration curves (*e.g.*,  $y = ax + b$ , x: concentration of drug, y: peak area)<sup>1, 8, 9</sup>.

4.4) Dilute the samples from the sorption study with methanol for diazepam or 5% dextrose for tacrolimus as appropriate so that they fall within the calibration range and directly inject 10 µL of diluted sample into the HPLC system.

### 5. Calculation of drug concentration and sorption level

5.1) Calculate the drug concentrations of the samples using calibration curves (unknown x and known y).

5.2) Calculate the sorption levels of the drugs using the following equation:

$$S = \left(1 - \frac{C_p}{C_o}\right) \times 100$$

where S: Sorption level (%)

C<sub>o</sub>: Drug concentration after the dilution of the injections (µg/mL)

C<sub>p</sub>: Drug concentration passed through the tubes (µg/mL)

## REPRESENTATIVE RESULTS:

The sorption to tubes in the administration set was kinetically monitored using the model drugs, diazepam (Figure 1a) and tacrolimus (Figure 1b), and the pump method (Figure 2). Diluted drug (Figure 2a) was passed through PVC- and non-PVC-based tubes (Figure 2b) at a fixed flow rate using an infusion pump (Figure 2c). The glass bottle was opened slightly to allow the insertion of the administration set tube. After the drug was delivered through the tubes (Figure 2d), samples were collected into amber vials (Figure 2e). All samples, including samples at the starting points, were analyzed using an HPLC method with UV detection (Figure 3a). Analysis conditions are listed in Table 1. For the preparation of drug standards, diazepam and tacrolimus were dissolved in methanol and acetonitrile because of their insolubility in 5% dextrose. The drug concentrations at the starting points of the sorption study were calculated from the analysis of the samples after the drug dilution. Sorption levels in PVC- and non-PVC-based tubes of administration sets were determined by calculating the percentage of remaining drug content after passage through the tubes from the calibration curves (Figure 3b) and subtracting these values from 100% (Figure 3c). The recommended acceptable range of drug sorption percentages was less than 10%, based on the content of injections from pharmacopoeias<sup>12</sup>. In addition, the specific drugs (e.g., anticancer drugs) should be confirmed with clinical guidelines. We determined whether drug sorption levels of the samples were appropriate (Figure 3d). Figure 4 and Figure 5 show representative chromatograms at low and high concentrations of drugs for standards and sample solutions, respectively. Retention time of each drug was 8.2 min for diazepam and 6.8 min for tacrolimus. There were no interfering peaks from the matrix. Specifically, in samples of the diazepam sorption study, the interfering peaks did not overlap with drug peak in the chromatogram, although a different solvent (5% dextrose) was used than in the standards. Table 2 shows calculations of representative sorption levels of diazepam and tacrolimus. The sorption level of each drug was the highest in PVC-based tubes, lower in PU-based tubes, and lowest in PO-based tubes at the initial phase of the kinetic sorption test.

## FIGURE LEGENDS:

**Figure 1. Chemical structures of model drugs: (a) diazepam and (b) tacrolimus.** Diazepam is a benzodiazepine derivative and tacrolimus is a 23-membered macrolide lactone. This figure has been modified<sup>1</sup>.

**Figure 2. Test set of a kinetic sorption study using a pump.** (a) Drug diluted with 5% dextrose in a bottle, (b) tube of administration set (1 m in length), (c) infusion pump, (d) drug passed through the tube, and (e) amber vials for storage. To minimize additional drug sorption, drug solutions and samples were prepared and stored in a glass bottle and amber vials for injections, respectively. This figure has been modified<sup>1</sup>.

**Figure 3. Key steps for evaluating drug sorption level to tubes of administration sets.** (a) Analysis of drug using an HPLC method with UV detection, calculation of (b) drug concentration from the calibration curve and (c) sorption level (%), and (d) recommendation of acceptable criteria for drug sorption. Several steps in the sorption evaluation, from drug selection to the sorption test, such as the analysis of drug concentration and the calculation of sorption levels, are described.

**Figure 4. Representative chromatograms of diazepam.** (a) Blank (methanol), standards at (b) 0.3125 µg/mL and (c) 20 µg/mL, and (d) sample (5% dextrose). The peak of diazepam was detected at 8.2 min, and fluctuations in retention time occurred within 1 min in the chromatograms. The peaks from the solvent were presented before the diazepam peak in the blank and standard chromatograms.

**Figure 5. Representative chromatograms of tacrolimus.** (a) Blank (acetonitrile with 5% dextrose), standards at (b) 2.5 µg/mL and (c) 20 µg/mL, and (d) sample. The tacrolimus peak at 6.8 min was successfully separated in a chromatogram. There were no peaks that overlapped with the tacrolimus peak. The peak was detected at 2.5 µg/mL, with a signal-to-noise ratio greater than 10.

**Table 1. HPLC conditions.**

**Table 2. Representative sorption results for diazepam and tacrolimus in PVC- and non-PVC-based tubes (n = 3)<sup>1</sup>.**

## **DISCUSSION:**

Drug sorption to administration sets is a cause of unexpected drug loss in intravenous drug delivery. During sorption, drugs are generally partitioned to polymeric materials of tubes at the early phase of infusion; after sorption equilibrium is reached, the delivered amount of drug is stabilized<sup>1</sup>. The sorption levels of drugs should be evaluated and minimized. Several evaluation methods for drug sorption have been studied, such as a pump method and a drip method. Compared to the drip method, the pump method can be easily manipulated without bias. Although administration sets with flow regulators (conventional form) are used in the drip method, desired flow rates less than 5 mL/h are hard to achieve. Therefore, we recommend the pump method for the sorption evaluation of tubes in administration sets.

When using the pump method, major factors that affect drug sorption to tubes of administration sets are drug properties (e.g., hydrophobicity and charge), conditions of the sorption test (e.g., drug concentration, flow rate, solvent compatibility, tube length, and temperature), analytical methods for drugs (e.g., HPLC and MS), and the tube polymers in the administration sets (e.g., PVC, PU, and PO)<sup>2-12</sup>. First, the selection of the model drugs is critical for obtaining precise and accurate experimental results. Even though diazepam management is tracked by the Psychotropic Drugs Control Act, we selected diazepam (Figure 1a) and tacrolimus (Figure 1b) as model drugs because of their high sorption levels to polymeric tubes of administration sets<sup>1</sup> or containers<sup>13, 14</sup>. In this case, drugs at high concentrations showed less sorption than those at low concentrations in the early phase of infusion<sup>1, 2</sup>. These drugs have high log P values (diazepam: 2.82<sup>15</sup>, tacrolimus: 3.96<sup>16</sup>) and low solubility, as categorized by the Biopharmaceutical Classification System (BCS class 2). Because of their hydrophobicity, these drugs can interact with tubes of administration sets, leading to sorption. Other drugs showing high sorption levels (e.g., nitroglycerin<sup>2</sup> and cyclosporin A<sup>3</sup>) can be used as alternative model drugs for sorption evaluation. Furthermore, macromolecular drugs,

such as biologics (antibody therapeutics, insulin, etc.), can be applied for the quality evaluation of administration sets regarding drug sorption<sup>12</sup>.

We set up a simple kinetic sorption study, using a pump to easily obtain precise results and to minimize artifacts. (Figure 2). In the pump method, drug solution (Figure 2a) was passed through a tube cut from the administration set (Figure 2b) after installation into an infusion pump (Figure 2c). Except for the tubes from administration sets, all devices (bottle, graduated cylinder, and sampling vials) were composed of chemically resistant borosilicate glass to prevent additional drug sorption to polymers. In this study, tubes without other accessories at a fixed length of 1 m were used to simplify the factors of drug sorption to tubes of administration sets. If a clinical condition requires it, a multiplication factor for the length of tube can be used. In the sorption test, the diluted drug solutions were used as the starting concentrations<sup>1,7</sup>. After delivery, the drug solution (Figure 2d) was collected into vials at various time points (Figure 2e). Drug solutions for sampling were passed completely through the tube at the preselected conditions of flow rate and sampling time points. Sorption generally occurs in the early phase of infusion, and the pattern is followed by a convection-interfacial resistance-diffusion model<sup>7</sup>. Diazepam sorption results are comparable to the double-lumen extension tube model<sup>17</sup> when the initial drug concentration is considered before delivery. Therefore, sampling time points can be modified so that sorption evaluation takes less time. All factors of the test conditions were confirmed based on the clinical usage of drugs.

In this protocol, we chose the HPLC method for drug analysis based on previous reports<sup>1,8,9</sup>. Simple and reproducible HPLC methods have been developed. The HPLC conditions are listed in Table 1. Various other techniques, such as MS and immunoassay, have also been developed as alternative analysis methods of drug concentrations<sup>10,11</sup>. MS/MS and immunoassay are highly sensitive for the detection of drugs and their metabolites. Specifically, an immunoassay can easily be performed without requiring large and expensive equipment for drug analysis.

Regarding the quality evaluation of administration sets, drug sorption to PVC- and non-PVC-based materials used in the tubes of administration sets has been studied. The evaluation of sorption to tubes in administration sets started with drug selection and ended with the consideration of acceptable criteria of sorption levels, as illustrated (Figure 3). PVC-based tubes showed high sorption levels for many drugs such as diazepam, tacrolimus (Table 2), nitroglycerin<sup>2</sup>, and cyclosporin A<sup>3</sup>. Among approaches to minimize drug sorption to the tubes of administration sets to less than 10%, alternative materials or polymeric combinations have been developed, such as PO-based materials and layer-by-layer designs<sup>2,13</sup>. The PE/PB/PP blended PO-based tube of an administration set used in this study showed low sorption levels, as a non-PVC-based tube. On the other hand, PE-based tubes are not used for administration sets, but they are commercially used in the market as a syringe extension tube due to their hardness.

This protocol can be applied to the quality control of administration sets with respect to drug sorption. More drugs classified by sorption level (highest, lower, and lowest) should be used in sorption evaluations for the quality assurance of administration sets. This protocol can also be used in scientific research for the development of new alternative polymeric materials or new designs for tubes in administration sets that do not result in drug sorption<sup>1, 13</sup>.

#### **ACKNOWLEDGEMENTS:**

This work was supported by the Korea Ministry of Environment (MOE) as part of the “The advancement of scientific research and technological development in environmental science program (E315-00015-0414-2).”

#### **DISCLOSURES:**

The authors have nothing to disclose.

#### **REFERENCES:**


1. Jin, S.E., You, S., Jeon, S., and Hwang, S.J. Diazepam sorption to PVC- and non-PVC-based tubes in administration sets with quantitative determination using a high-performance liquid chromatographic method. *Int. J. Pharm.* **506**, 414-419, doi:10.1016/j.ijpharm.2016.04.040 (2016).
2. Treleano, A., Wolz, G., Brandsch, R., and Welle, F. Investigation into the sorption of nitroglycerin and diazepam into PVC tubes and alternative tube materials during application. *Int. J. Pharm.* **369**, 30-37, doi:10.1016/j.ijpharm.2008.10.024 (2009).
3. Shibata, N., et al. Adsorption and pharmacokinetics of cyclosporin A in relation to mode of infusion in bone marrow transplant patients. *Bone Marrow Transplant.* **25**, 633-638, doi:10.1038/sj.bmt.1702196 (2000).
4. Kawano, K., Tsubouchi, R., and Nakajima, S. The Effect of the Drip Condition (Container Materials, Concentration, Drip Rate) on the Sorption of Nicardipine Hydrochloride from Injection to the Intravenous Infusion Set. *Jap. J. Hosp. Pharm.* **18**, 491-495, doi:10.5649/jjphcs1975.18.491 (1992).
5. Hanawa, T., et al. Investigation of the release behavior of diethylhexyl phthalate from the polyvinyl-chloride tubing for intravenous administration. *Int. J. Pharm.* **210**, 109-115, doi:10.1016/S0378-5173(00)00578-0 (2000).
6. Mason, N.A., Cline, S., Hyneck, M.L., Berardi, R.R., Ho, N.F., and Flynn, G.L. Factors affecting diazepam infusion: solubility, administration-set composition, and flow rate. *Am. J. Hosp. Pharm.* **38**, 1449-1454, <http://www.ncbi.nlm.nih.gov/pubmed/7294034> (1981).
7. Roberts, M.S. Modeling solute sorption into plastic tubing during organ perfusion and intravenous infusions. *J. Pharm. Sci.* **85**, 655-665, doi:10.1021/js9500621 (1996).
8. Patel, P., Panchal, S., Mehta, T., Solanki, S., and Patel, C. Reversed-Phase High Performance Liquid Chromatographic (RP-HPLC) Method For Determination of tacrolimus in bulk and pharmaceutical formulation. *Int. J. Pharm. Pharm. Sci.* **3**, 220-222 (2011).
9. Mercolini, L., Mandrioli, R., Iannello, C., Matrisciano, F., Nicoletti, F., and Raggi, M.A. Simultaneous analysis of diazepam and its metabolites in rat plasma and brain tissue by HPLC-UV and SPE. *Talanta* **80**, 279-285, doi:10.1016/j.talanta.2009.06.074 (2009).

10. Wang, X., et al. Deposition of diazepam and its metabolites in hair following a single dose of diazepam. *Int. J. Legal. Med.* In press doi: 10.1007/s00414-016-1429-x (2016).
11. Wallemacq, P., et al. Multi-site Analytical Evaluation of the Abbott ARCHITECT Tacrolimus Assay. *Ther. Drug. Monit.* **31**(2), 198-204. doi: 10.1097/FTD.0b013e31819c6a37 (2009).
12. Morar-Mitrica, S., et al. Development of a stable low-dose aglycosylated antibody formulation to minimize protein loss during intravenous administration. *MAbs.* **7**(4), 792-803, doi: 10.1080/19420862.2015.1046664 (2015).
13. Trissel, L.A., Xu, Q.A., and Baker, M. Drug compatibility with new polyolefin infusion solution containers. *Am. J. Health Syst. Pharm.* **63**, 2379-2382, doi:10.2146/ajhp060191 (2006).
14. Cloyd, J.C., Vezeau, C., and Miller, K.W. Availability of diazepam from plastic containers. *Am. J. Hosp. Pharm.* **37**, 492-496, <http://www.ncbi.nlm.nih.gov/pubmed/7377211>(1980).
15. Ceccherini, G., Perondi, F., Lippi, I., Grazia, G., and Marchetti, V. Intravenous lipid emulsion and dexmedetomidine for treatment of feline permethrin intoxication: a report from 4 cases. *Open Veterinary Journal*, **5**(2), 113-121, <https://www.ncbi.nlm.nih.gov/pubmed/26623376> (2015).
16. Lei, W., Yu, C., Lin, H., and Zhou, X. Development of tacrolimus-loaded transfersomes for deeper skin penetration enhancement and therapeutic effect improvement in vivo. *Asian J. Pharm. Sci.* **8**, 336-345, doi:10.1016/j.ajps.2013.09.005 (2013).
17. Maiguy-Foinard, A., Blanchemain, N., Barthelemy, C., Decaudin, B., and Odou, P., Influence of a double-lumen extension tube on drug delivery: examples of isosorbide dinitrate and diazepam. *PLoS One.* **11**(5), e0154917. doi:10.1371/journal.pone.0154917 (2016).


The chemical structure shows a benzodiazepine core. A benzene ring is fused to a seven-membered diazepine ring. The diazepine ring has a methyl group (H<sub>3</sub>C) attached to the nitrogen at position 1, a carbonyl group (C=O) at position 5, and a double bond between positions 2 and 3. A phenyl ring is attached to position 2, and a 3-chlorophenyl ring is attached to position 3. The chlorine atom (Cl) is at the meta position of the phenyl ring.





The chemical structure is a complex macrocycle with the following features:





- A large ring containing several stereocenters marked with wedges and dashes.
- Functional groups include hydroxyl (OH), methoxy (OCH<sub>3</sub>), and methyl (H<sub>3</sub>C) groups.
- A cyclic amide (lactam) is present on the left side of the structure.
- A terminal vinyl group (CH=CH<sub>2</sub>) is attached to the right side of the ring.
- The structure is highly branched and contains multiple oxygen atoms, including those in the amide and ether linkages.











HPLC condition	Drug	
	Diazepam	Tacrolimus
Mobile phase	A mixture of acetonitrile, methanol, and sodium phosphate buffer* (29:47:24, v/v/v, adjusted to pH 3.1 with phosphoric acid) *Sodium dihydrogen phosphate 1.2 g/L in distilled water	Acetonitrile (100%)
Flow rate	0.1 mL/min	0.1 mL/min
UV wavelength	232 nm	213 nm
Run time	10 min	10 min
Retention time	8.2 min	6.8 min

Drug	Sorption (%)		
	PVC	PU	PO
Diazepam (0.05 h)	27.6 ± 3.0	21.9 ± 12.6	11.3 ± 4.6
Tacrolimus (1.05 h)	15.1 ± 3.3	10.3 ± 6.3	0.6 ± 0.9

Name of Reagent/ Equipment	Company	Catalog Number	Comments/ Description
PVC IV sets	Becton Dickinson (BD) Co. Ltd. (Franklin Lakes, NJ, USA)		Internal diameter: 2.54 mm
PU IV sets	Tianjin Hanaco Medical (THM) Co.Ltd. (Tianjin, China)		Non-PVC Internal diameter: 2.54 mm
Non-PVC Polyolefin IV sets	Polysciencetech, Co. Ltd (Anseong, Korea)		Non-PVC [PE elastomer/PP elastomer/PB elastomer(25/50/25, weight ratio) blend] Internal diameter: 2.54 mm
Syringe	Korea Vaccine Co. Ltd. (Seoul, Korea)	KOVAX-SYRINGE 1 mL 26G 1/2"	
Daewon diazepam injection	Daewon Pharma. Co. Ltd. (Hwaseong, Gyunggi, Korea)		1 mg/mL, total 2 mL Batch No.: P003 Composition: diazepam, propylene glycol, ethanol, benzyl alcohol, sodium benzoate, benzoic acid, water for injection
Tacrobrel injection	Chong Keun Dang, Co. Ltd. (Seoul, Korea)		5 mg/mL, total 1 mL Batch No.: AG002 Composition: tacrolimus hydrate, polyoxyl 60 hydrogenated castor oil (HCO-60), dehydrated alcohol
5% Dextrose	JW Pharmaceutical (Seoul, Korea)	500 mL	
5% Dextrose	Daehan Pharmaceutical (Seoul, Korea)	200 mL	Bottle (glass)
Amber vials		20 mL	Glass
Terumo infusion pump	Terumo (Medical Corp., USA)	TE-135	
HPLC system with UV detector	Agilent (Santa Clara, CA, USA)	Agilent 1260	
CAPCELL PAK C <sub>18</sub> column	Shiseido (Japan)	90404	1.5 mm x 250 mm, 5 µm
Diazepam			From Daewon Pharma. Co., Ltd.
Tacrolimus	Teva Czech industries (Czech Republic)		From Chong Keun Dang, Co. Ltd.
Acetonitrile	Burdick and Jackson Co., Ltd. (MI, USA)	3/1/9017	

Methanol	Burdick and Jackson Co. Ltd. (MI, USA)	AH230-4	
Water	Burdick and Jackson Co. Ltd. (MI, USA)	3/1/4218	
Sodium dihydrogen phosphate	Sigma (St. Louis, MO, USA)		
Phosphoric acid	Sigma (St. Louis, MO, USA)		



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article: Evaluation method of drug sorption to PVC and non-PVC-based tubes in administration sets using a pump

Author(s): Su-Eon Jin, Siwon Yoon, Seunghe Jeon, Hyo-Jin Pyon, Sung-Joo Hwang

Item 1 (check one box): The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via: ☒ Standard Access ☐ Open Access

Item 2 (check one box):

- ☒ The Author is NOT a United States government employee.
- ☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.
- ☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: **"Agreement"** means this Article and Video License Agreement; **"Article"** means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; **"Author"** means the author who is a signatory to this Agreement; **"Collective Work"** means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; **"CRC License"** means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; **"Derivative Work"** means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; **"Institution"** means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; **"JoVE"** means MyJoVE Corporation, a Massachusetts corporation and the publisher of *The Journal of Visualized Experiments*; **"Materials"** means the Article and / or the Video; **"Parties"** means the Author and JoVE; **"Video"** means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4** and **7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this Section 6 is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such

statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

9. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

10. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have



## ARTICLE AND VIDEO LICENSE AGREEMENT

full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

11. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's

expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

12. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

13. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement required per submission.

### CORRESPONDING AUTHOR:

Name: SUNG-JOO HWANG  
Department: Department of Pharmaceutics, College of Pharmacy  
Institution: Yonsei University  
Article Title: Evaluation method of drug sorption to PVC- and non-PVC-based tubes  
Signature: [Handwritten Signature] Date: 6/7/2016

Please submit a signed and dated copy of this license by one of the following three methods:

- 1) Upload a scanned copy of the document as a pdf on the JoVE submission site;
- 2) Fax the document to +1.866.381.2236;
- 3) Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02139

For questions, please email [submissions@jove.com](mailto:submissions@jove.com) or call +1.617.945.9051

**Manuscript No.: JoVE55086R2**

**Title: Evaluation method for drug sorption to PVC- and non-PVC-based tubes in administration sets using a pump**

### Response for comments:

Thank you for the careful Peer Review revisions that were made to the manuscript. The following editorial comments need to be addressed.

- Your manuscript has been modified by your editor, please maintain the current formatting throughout the manuscript. Please use the updated manuscript located in your Editorial Manager account (under “File Inventory”) for all subsequent revisions. The updated manuscript is also attached.

#### • 1.3: How are the tubes cut precisely? Sharp razor?

→ Recommendation added.

### PROTOCOL

#### 1. Preparation of tubes in administration sets

Note: Perform the cutting step precisely to eliminate the effect of differences in tube length on drug sorption. Use a sharp razor.

#### • 2.1: Please re-write for grammar and clarity.

2.1) Label the bottle with the name (e.g., diazepam and tacrolimus).

→2.1) Add a label indicating drug name (e.g., diazepam or tacrolimus) to the bottle.

#### • 2.2. Note: Please re-write for grammar and clarity.

2.2) Dilute drug injections to the following concentrations in bottled 5% dextrose solution: diazepam injections, 1 mg/mL to 100 µg/mL (10 mL of diazepam injection in 100 mL) and tacrolimus injections, 5 mg/mL to 10 µg/mL (200 µL of tacrolimus injection in 100 mL)

→2.2) Dilute drug injections with 5% dextrose solution: from 1 mg/mL to 100 µg/mL for diazepam injections (10 mL of diazepam injection in 100 mL of 5% dextrose solution) and from 5 mg/mL to 10 µg/mL for tacrolimus injections (200 µL of tacrolimus injection in 100 mL of 5% dextrose solution).

#### • Protocol section 3.2: Please clarify how to insert the middle of the preloaded tube into the infusion pump. It is not clear what the “middle” of the tube indicates.

→To clarify the protocol 3.2, we added the inside of an infusion pump in Figure 2 and corrected the unclear part.




Figure 2. Test set of kinetic sorption study using a pump. (a) Drug diluted with 5% dextrose in a bottle, (b) tube of administration set (1 m in length), (c) infusion pump, (d) drug passed through the tube, and (e) amber vials for storage. To minimize additional drug sorption, drug solutions and samples were prepared and stored in a glass bottle and amber vials for injections, respectively. This figure has been modified<sup>1</sup>.

• **3.2.4: What does the glass graduated cylinder contain?**

→The glass graduated cylinder is made of chemically resistant borosilicate glass and used to collect the drug solutions without additional sorption to polymeric materials.

3.2.4) Put the end of tubes into a glass graduated cylinder after removing the syringe.

→3.2.4) Put the end of tube into a chemically resistant borosilicate glass graduated cylinder, which is used to collect drug solution after passing through the tube.

• **Figure 4 legend: Please clarify “In the chromatogram, solvent peak was presented before diazepam peak”.**

**Figure 4. Representative chromatograms of diazepam.** (a) Blank (methanol), standard at (b) 0.3125 µg/mL and (c) 20 µg/mL, and (d) sample in 5% dextrose. The peak of diazepam was detected at 8.2 min and fluctuations in retention time occurred within 1 min in the chromatograms. In the chromatogram, solvent peak was presented before diazepam peak.

→**Figure 4. Representative chromatograms of diazepam.** (a) Blank (methanol), standards at (b) 0.3125 µg/mL and (c) 20 µg/mL, and (d) sample (5% dextrose). The peak of diazepam was detected at 8.2 min, and fluctuations in retention time occurred within 1 min in the chromatograms. The peaks from solvent were presented before the diazepam peak in the chromatograms of blank and standard.

• **Table 2: Please provide at least replicate data. Data from previous publication is acceptable.**

→We added the data in Table 2. Results are expressed the mean ± SD (n=3).

**Table 2. Representative sorption results for diazepam and tacrolimus in PVC- and non-PVC-based tubes (n=3)<sup>1</sup>.**

Drug	Sorption (%)		
	PVC	PU	PO
Diazepam (0.05 h)	27.6 ± 3.0	21.9 ± 12.6	11.3 ± 4.6
Tacrolimus (1.05 h)	15.1 ± 3.3	10.3 ± 6.3	0.6 ± 0.9

• **Please expand your discussion to cover the following in detail and in paragraph form: 1) modifications and troubleshooting, 2) limitations of the technique, 3) significance with respect to existing methods, 4) future applications and 5) critical steps within the protocol. Several points have been deleted and must be added.**

→We clarify the limitations of the technique, significance with respect to existing methods, future applications and critical steps within the protocol.

## DISCUSSION

Drug sorption to administration sets is a cause of unexpected drug loss in intravenous drug delivery. During sorption, drugs are generally partitioned to polymeric materials of tubes at the early phase of infusion; after sorption equilibrium is reached, the delivered amount of drugs is stabilized<sup>1</sup>. The sorption levels of drugs should be evaluated and minimized. Several evaluation methods for drug

sorption have been studied, such as a pump method and a drip method. Compared to the drip method, the pump method can be easily manipulated without bias. Although administration sets with flow regulators (conventional form) are used in the drip method, desired flow rates less than 5 mL/h are hard to achieve. Therefore, we recommend the pump method for sorption evaluation of tubes in administration sets. **(3) significance with respect to existing methods)**

When using the pump method, major factors that affect drug sorption to tubes of administration sets are classified by drug properties (e.g., hydrophobicity, charge), conditions of sorption test (e.g., drug concentration, flow rate, solvent compatibility, tube length, temperature), analytical methods for drugs (e.g., HPLC, MS), and polymers of tubes in the administration sets (e.g., PVC, PU, PO)<sup>2-12</sup>. **(5) critical steps within the protocol)** First, selection of the model drugs is critical for obtaining precise and accurate experimental results. Even though diazepam management is tracked by the Psychotropic Drugs Control Act, we selected diazepam (Figure 1a) and tacrolimus (Figure 1b) as model drugs because of their high sorption levels to polymeric tubes of administration sets<sup>1</sup> or containers<sup>13, 14</sup>. In this case, drugs at high concentrations showed less sorption than those at low concentrations in the early phase of infusion<sup>1, 2</sup>. These drugs have high log P values (diazepam - 2.82<sup>15</sup>, tacrolimus - 3.96<sup>16</sup>) and low solubility as categorized by the Biopharmaceutical Classification System (BCS class 2). Because of their hydrophobicity, these drugs can interact with tubes of administration sets, leading to sorption. Other drugs showing high sorption levels (e.g., nitroglycerin<sup>2</sup> and cyclosporin A<sup>3</sup>) can be used as alternative model drugs for sorption evaluation. Furthermore, macromolecular drugs such as biologics (antibody therapeutics, insulin, etc.) can be applied for quality evaluation of administration sets regarding drug sorption<sup>12</sup>. **(1) modifications and troubleshooting)**

Next, we set up a simple kinetic sorption study using a pump to easily obtain the precise results, and minimize artifacts. (Figure 2). In the pump method, drug solution (Figure 2a) was passed through a tube cut from the administration set (Figure 2b) after installation into an infusion pump (Figure 2c). Except for the tubes from administration sets, all devices (bottle, graduated cylinder, and sampling vials) were composed of chemically resistant borosilicate glass to prevent additional drug sorption to polymers. **(5) critical steps within the protocol)** In this study, tubes without other accessories at a fixed length of 1 m were used to simplify the factors of drug sorption to tubes of administration sets. **(2) limitations of the technique)** If a clinical condition requires it, we can use a multiplication factor for a length of tube. **(1) modifications and troubleshooting)** In the sorption test, the diluted drug solutions were used as starting concentrations<sup>1, 7</sup>. After delivery, the drug solution (Figure 2d) was collected into vials at various time points (Figure 2e). Drug solutions for sampling were passed completely through the entire tube at the preselected conditions of flow rate and sampling time points. Sorption generally occurs in the early phase of infusion and the pattern is followed by convection-interfacial resistance-diffusion model<sup>7</sup>. Comparing with double-lumen extension tube model<sup>17</sup>, diazepam sorption results are comparable when the initial drug concentration is considered before delivery. Therefore, sampling time points can be modified so that sorption evaluation takes less time. All factors of test conditions were confirmed based on the clinical usage of drugs. **(1) modifications and troubleshooting)**

In this protocol, we chose the HPLC method for drug analysis based on previous reports<sup>1, 8, 9</sup>. Simple and reproducible HPLC methods have been developed. The HPLC conditions are listed in Table 1. Various other techniques such as MS and immunoassay have also been developed as alternative analysis methods of drug concentrations<sup>10, 11</sup>. MS/MS and immunoassay are highly sensitive for detection of drugs and their metabolites. Specifically, immunoassay can be easily performed without requiring large and expensive equipment for drug analysis. **(1) modifications and troubleshooting)**

Regarding quality evaluation of administration sets, drug sorption to PVC- and non-PVC-based materials used in the tubes of administration sets has been studied. Evaluation of sorption to tubes in administration sets started with drug selection and ended with consideration of acceptable criteria of sorption levels as illustrated (Figure 3). PVC-based tubes showed high sorption levels for many drugs such as diazepam, tacrolimus (Table 2), nitroglycerin<sup>2</sup>, and cyclosporin A<sup>3</sup>. Among approaches to minimize drug sorption in the tubes of administration sets to less than 10%, alternative materials or designs of polymeric combinations have been developed, such as PO-based materials and layer-by-layer designs<sup>2, 13</sup>. PE/PB/PP blended PO-based tube of administration set used in this study, showed



low sorption level as non-PVC-based tube. On the other hand, PE-based tubes are not used for the administration sets, but commercially used in the market as a syringe extension tube due to their hardness.

This protocol can be applied for the quality control of administration sets with respect to drug sorption. More drugs classified by sorption level (highest, lower, and lowest) should be used in sorption evaluation for quality assurance of administration sets. This protocol can also be used in scientific research for development of new alternative polymeric materials or new designs for tubes in administration sets that do not result in drug sorption<sup>1, 13</sup>. (4) future applications)

• **Please copy edit your manuscript. There are a number of grammatical errors throughout. We recommend that you have a native English speaker copy-edit the manuscript.**

→We have an English editing service with a native English speaker. Grammatical errors have been corrected.

• **Please discuss the limitations of the method in the Discussion section.**


→We discussed 2) limitations of the method as mentioned above.

## DISCUSSION

~. In this study, tubes without other accessories at a fixed length of 1 m were used to simplify the factors of drug sorption to tubes of administration sets. If a clinical condition requires it, we can use a multiplication factor for a length of tube.~

• **Figure 1: Is this Figure from Wikipedia? If you are re-using figures (e.g. Figures 1 and 2) from a previous publication, please obtain explicit permission to re-use the figure from the previous publisher (this can be in the form of a letter from an editor or a link to the editorial policies that allows you to re-publish the figure). Please upload the text of the re-print permission (may be copied and pasted from an email/website) as a Word document to the Editorial Manager site in the "Supplemental files (as requested by JoVE)" section.**

→We redraw chemical structures of diazepam and tacrolimus.



**Figure 1. Chemical structures of model drugs: (a) diazepam and (b) tacrolimus.** Diazepam is a benzodiazepine derivative, and tacrolimus is a 23-membered macrolide lactone. This figure has been modified<sup>1</sup>.

• **Please note that the reviewers raised some significant concerns regarding your method and your manuscript. Please address and/or expand on the following comments in the manuscript:**

### Reviewer #1:

• **The main part step 3.2 is not clear enough. Subsequently the related figure (#2) is not well**

*illustrated. The "middle part" is nonsense and also after "removing the syringe" the open end is left inside the drug solution or what?*

→To clarify the protocol 3.2, we added the inside of an infusion pump in Figure 2 and corrected the unclear part as mentioned above.




Figure 2. Test set of kinetic sorption study using a pump. (a) Drug diluted with 5% dextrose in a bottle, (b) tube of administration set (1 m in length), (c) infusion pump, (d) drug passed through the tube, and (e) amber vials for storage. To minimize additional drug sorption, drug solutions and samples were prepared and stored in a glass bottle and amber vials for injections, respectively. This figure has been modified<sup>1</sup>.

**• Step 4.3.1: Not all drugs can be quantified using UV detector. It should be considered here.**

→We added the note for the detection method.

4.3) Analyze standards using the HPLC method with UV detection<sup>1, 8, 9</sup>.

Note: Use an appropriate detection method (UV, fluorescence, etc) for drug analysis.

#### Reviewer #2:

*• The sorption model proposed by Su-Eon Jin et al isn't an innovative concept. Provided data are inadequate in view of recent literature on the subject, e.g. the article of Foinard et al (PlosOne, 2016). This model doesn't correspond to a standardized method or guidelines because it couldn't be applied to any drug solution. It has been specifically performed on 2 drugs wellknown to absorb in PVC material : diazepam and tacrolimus, in very specific clinical conditions. The latter may be very different according the drugs tested. Here, specific parameters are tested:*

- administration procedure : with a pump procedure, using a syringe pump
- length of tubes (which could influence the sorption)
- flow rate : because they are plenty of different flow rates used in clinical practice (especially considering adults or children patients and also considering the indication)
- specific tested concentrations: they may represent the therapeutic use of drugs. If several dosings do exist according the indication, they all have to be tested (especially for diazepam in this study)
- the acceptable criteria of drug sorption ( $\pm 10\%$ ) : nowadays, some drugs' stabilities have to match an acceptable range less than 5% because of the physicochemical nature and the toxicity of the drugs. Such is the case for instance of anticancer agents, as it is recommended in the last SFPO (Société Française de Pharmacie Oncologique) guidelines (Bardin et al, Annales Pharmaceutiques Françaises 2011)
- etc...

*\*This comment was not satisfactorily addressed in the manuscript. Please discuss the points made in the rebuttal letter in the manuscript. Please note that the authors' rebuttal was not clear and did not address the reviewer's comments.*

→ Sorption model used in Jin et al. is already proposed by Roberts (reference: 7. Roberts, M.S. Modeling solute sorption into plastic tubing during organ perfusion and intravenous infusions. *J. Pharm. Sci.* **85**, 655-665, doi:10.1021/js9500621 (1996).). This model is designed as nonlinear regression with a convection-interfacial resistance-diffusion based on the preloaded tube model with

solution. This model has been confirmed. We also checked the test conditions (Jin et al.). We used this model to explain our data set and confirmed whether the pattern was matched or not.

The model proposed by Foinard et al. is not new. Foinard et al. didn't consider the initial point of drug concentration before delivery in sorption study. If they consider the concentration of drug at real "0" time of starting point, their concentration level should be started with 100%. Then, it is the same as Roberts. We think the model from Roberts can correspond to a standardized method or regulatory guidelines because sorption level should be compared with the drug concentration at starting point.

Although diazepam and tacrolimus are highly sorptive drugs categorized by BCS class II, their sorption levels are different in various types of tubes. Specifically sorption levels of diazepam and tacrolimus are lowered in PO-based tubes of administration sets than other tubes of administration sets. We recommended the protocol to minimize the affecting factors for drug sorption by fixing several parameters. This protocol is designed to perform easily. The acceptable criteria of drug sorption using our protocol with recommended drugs were lower than 10%. In the case of specific drugs, it should be included in pharmacopoeia or prescribing information.

→ We added the reviewer's comment in protocol and discussion of the manuscript.

## REPRESENTATIVE RESULTS

~The recommended acceptable range of drug sorption percentages was less than 10%, based on the content of injections from pharmacopoeias<sup>12</sup>. In addition, the specific drugs (e.g., anticancer drugs) should be confirmed with clinical guidelines.~

## DISCUSSION

~ When using the pump method, major factors that affect drug sorption to tubes of administration sets are classified by drug properties (e.g., hydrophobicity, charge), conditions of sorption test (e.g., drug concentration, flow rate, solvent compatibility, tube length, temperature), analytical methods for drugs (e.g., HPLC, MS), and polymers of tubes in the administration sets (e.g., PVC, PU, PO)<sup>2-12</sup>. First, selection of the model drugs is critical for obtaining precise and accurate experimental results. Even though diazepam management is tracked by the Psychotropic Drugs Control Act, we selected diazepam (Figure 1a) and tacrolimus (Figure 1b) as model drugs because of their high sorption levels to polymeric tubes of administration sets<sup>1</sup> or containers<sup>13, 14</sup>. In this case, drugs at high concentrations showed less sorption than those at low concentrations in the early phase of infusion<sup>1, 2</sup>. These drugs have high log P values (diazepam - 2.82<sup>15</sup>, tacrolimus - 3.96<sup>16</sup>) and low solubility as categorized by the Biopharmaceutical Classification System (BCS class 2). Because of their hydrophobicity, these drugs can interact with tubes of administration sets, leading to sorption. Other drugs showing high sorption levels (e.g., nitroglycerin<sup>2</sup> and cyclosporin A<sup>3</sup>) can be used as alternative model drugs for sorption evaluation. Furthermore, macromolecular drugs such as biologics (antibody therapeutics, insulin, etc.) can be applied for quality evaluation of administration sets regarding drug sorption<sup>12</sup>.

Next, we set up a simple kinetic sorption study using a pump to easily obtain the precise results, and minimize artifacts. (Figure 2). In the pump method, drug solution (Figure 2a) was passed through a tube cut from the administration set (Figure 2b) after installation into an infusion pump (Figure 2c). Except for the tubes from administration sets, all devices (bottle, graduated cylinder, and sampling vials) were composed of **chemically resistant borosilicate** glass to prevent additional drug sorption to polymers. In this study, tubes without other accessories at a fixed length of 1 m were used to simplify the factors of drug sorption to tubes of administration sets. If a clinical condition requires it, we can use a multiplication factor for a length of tube. In the sorption test, the diluted drug solutions were used as starting concentrations<sup>1, 7</sup>. After delivery, the drug solution (Figure 2d) was collected into vials at various time points (Figure 2e). Drug solutions for sampling were passed completely through the entire tube at the preselected conditions of flow rate and sampling time points. Sorption generally occurs in the early phase of infusion and the pattern is followed by convection-interfacial resistance-diffusion model<sup>7</sup>. Comparing with double-lumen extension tube model<sup>17</sup>, diazepam sorption results are comparable when the initial drug concentration is considered before delivery. Therefore, sampling time points can be modified so that sorption evaluation takes less time. All factors of test conditions



were confirmed based on the clinical usage of drugs.

In this protocol, we chose the HPLC method for drug analysis based on previous reports<sup>1, 8, 9</sup>. Simple and reproducible HPLC methods have been developed. The HPLC conditions are listed in Table 1. Various other techniques such as MS and immunoassay have also been developed as alternative analysis methods of drug concentrations<sup>10, 11</sup>. MS/MS and immunoassay are highly sensitive for detection of drugs and their metabolites. Specifically, immunoassay can be easily performed without requiring large and expensive equipment for drug analysis.

Regarding quality evaluation of administration sets, drug sorption to PVC- and non-PVC-based materials used in the tubes of administration sets has been studied. Evaluation of sorption to tubes in administration sets started with drug selection and ended with consideration of acceptable criteria of sorption levels as illustrated (Figure 3). PVC-based tubes showed high sorption levels for many drugs such as diazepam, tacrolimus (Table 2), nitroglycerin<sup>2</sup>, and cyclosporin A<sup>3</sup>. Among approaches to minimize drug sorption in the tubes of administration sets to less than 10%, alternative materials or designs of polymeric combinations have been developed, such as PO-based materials and layer-by-layer designs<sup>2, 13</sup>. PE/PB/PP blended PO-based tube of administration set used in this study, showed low sorption level as non-PVC-based tube. On the other hand, PE-based tubes are not used for the administration sets, but commercially used in the market as a syringe extension tube due to their hardness. ~

**• Administration sets in polyethylene have not be tested here. Why? If such material is marketed, it should also be evaluated for drug sorption. Please mention the details presented in the rebuttal letter in the Discussion section. It is not clear what the authors are trying to convey here.**

→ Polyethylene (PE)-based tubes are not currently available in the market of administration sets because only PE-based tubes are too hard to use as tubes of administration sets. They are used in syringe extension sets. We used blended PO tubes of administration sets.

## DISCUSSION

~ Among approaches to minimize drug sorption in the tubes of administration sets to less than 10%, alternative materials or designs of polymeric combinations have been developed, such as PO-based materials and layer-by-layer designs<sup>2, 13</sup>. PE/PB/PP blended PO-based tube of administration set used in this study, showed low sorption level as non-PVC-based tube. On the other hand, PE-based tubes are not used for the administration sets, but commercially used in the market as a syringe extension tube due to their hardness.~

**• The administration sets are cut to 1m length. Why? It doesn't reflect clinical conditions because the devices often are more than 1.5m length: Author response (from the rebuttal letter): To remove the accessories of administration sets except tubes, we cut the tubes. If we use shorter length of tubes like 1 m in length, it takes shorter time to evaluate the drug sorption to tubes of administration sets. For considering a length factor of tube, it can reflect clinical conditions. Overall, it makes a protocol simple and easy to perform based on the clinical conditions. This comment was not satisfactorily addressed. Is the tube cut to 1 m for simplicity and easy of performance? In that case, it does not reflect the clinical settings.**

→We already mentioned the length of tubes for sorption test. The tube cut to 1 m is not a clinical setting, but it can be easily multiplied for the total length of tubes to reflect the clinical settings. We mentioned it in discussion.

## DISCUSSION

~Next, we set up a simple kinetic sorption study using a pump to easily obtain the precise results, and minimize artifacts. (Figure 2). ~ In this study, tubes without other accessories at a fixed length of 1 m were used to simplify the factors of drug sorption to tubes of administration sets. If a clinical condition requires it, we can use a multiplication factor for a length of tube. After delivery, the drug solution

(Figure 2d) was collected into vials at various time points (Figure 2e).~

• *There is no kinetic study (results) as mentioned by the authors. The results show only a percentage value of sorption at the end of the study. Values at each kinetic time have to be presented (table or graph). Please elaborate on your published kinetic study in the results section. Please provide the reference.*

→We already provided the kinetic data for sorption study (Jin et al., 2016). Highest sorption level from the previous study (Jin et al., 2016) showed in the early phase of kinetic study. Thus, we provided the initial sorption levels of the drugs as representative results. We added the reference in Table 2 and mentioned the kinetics in discussion.

## REPRESENTATIVE RESULTS

**Table 2. Representative sorption results for diazepam and tacrolimus in PVC- and non-PVC-based tubes (n=3)<sup>1</sup>.**

Drug	Sorption (%)		
	PVC	PU	PO
Diazepam (0.05 h)	27.6 ± 3.0	21.9 ± 12.6	11.3 ± 4.6
Tacrolimus (1.05 h)	15.1 ± 3.3	10.3 ± 6.3	0.6 ± 0.9

## DISCUSSION

Drug sorption to administration sets is a cause of unexpected drug loss in intravenous drug delivery. During sorption, drugs are generally partitioned to polymeric materials of tubes at the early phase of infusion; after sorption equilibrium is reached, the delivered amount of drugs is stabilized<sup>1</sup>. ~ Drug solutions for sampling were passed completely through the entire tube at the preselected conditions of flow rate and sampling time points. Sorption generally occurs in the early phase of infusion and the pattern is followed by convection-interfacial resistance-diffusion model<sup>7</sup>. Comparing with double-lumen extension tube model<sup>17</sup>, diazepam sorption results are comparable when the initial drug concentration is considered before delivery. Therefore, sampling time points can be modified so that sorption evaluation takes less time. All factors of test conditions were confirmed based on the clinical usage of drugs.~

### Reviewer #4:

• *At any point during the process, are you testing the starting concentration of the drug solution in the glass bottle? If not, this should be included as a baseline (control). Author response: We tested the starting concentration of drug solution in Jin et al. 2016. We collected the samples after drug dilution in a bottle and analyzed. Please mention if and when the starting concentration of drug solution is measured in the JoVE manuscript results section. Please provide the reference.*

→Thank you for the comments. We used the starting concentration of the drug solution in a glass bottle as a control. We also clarified the results from protocol 5.2. References are added in the discussion.

## REPRESENTATIVE RESULTS

~ All samples including samples at starting points were analyzed using an HPLC method with UV detection (Figure 3a). Analysis conditions are listed in Table 1. ~ The drug concentrations at starting points of the sorption study were calculated from the analysis of samples after drug dilution. Sorption levels in PVC- and non-PVC-based tubes of administration sets were determined by calculating the percentage of remaining drug content after passage through the tubes from the calibration curves (Figure 3b) and subtracting these values from 100% (Figure 3c).~

## DISCUSSION

~ In the sorption test, the diluted drug solutions were used as starting concentrations<sup>1,7</sup>. After delivery, the drug solution (Figure 2d) was collected into vials at various time points (Figure 2e). Drug solutions for sampling were passed completely through the entire tube at the preselected conditions of flow rate and sampling time points. Sorption generally occurs in the early phase of infusion and the pattern is followed by convection-interfacial resistance-diffusion model<sup>7</sup>. Comparing with double-lumen extension tube model<sup>17</sup>, diazepam sorption results are comparable when the initial drug concentration is considered before delivery. Therefore, sampling time points can be modified so that sorption evaluation takes less time. All factors of test conditions were confirmed based on the clinical usage of drugs.~

• *Was the glassware used in this experiment silanized or otherwise coated? If not, are there any scenarios in which it may need to be? Please address this comment in the Discussion section.*

→The glassware was made of chemically resistant borosilicate glass. We mentioned it in the manuscript at protocol 3, specifically 3.2.4 and discussion section.

## PROTOCOL

~3. Kinetic sorption study using an infusion pump

Note: Confirm tube-dependent flow rate using a pump prior to the sorption test due to the hardness of tubes. Collect samples at precise time points and use glass bottles and vials to prevent additional drug sorption during storage. Perform the test as shown in Figure 2. Protect the drug solution against light if the drug has photosensitivity. Perform the experiments in triplicate.

- 3.1) Without creating air bubbles, preload a diluted solution of the drug into the tube using a syringe.
  - 3.1.1) Connect one end of the tube to a syringe.
  - 3.1.2) Put the other end of the tube into the bottled drug solution.
  - 3.1.3) Pull back the syringe plunger until the tube is completely filled with the drug solution.
- 3.2) Install the tube into an infusion pump.
  - 3.2.1) Open the door of the infusion pump and push the release lever.
  - 3.2.2) Insert the middle of the preloaded tube into the infusion pump and keep it straight.
  - 3.2.3) Remove the syringe at the end of the tube after installation of tube.
  - 3.2.4) Put the end of tube into a chemically resistant borosilicate glass graduated cylinder, which is used to collect drug solution after passing through the tube.~

## DISCUSSION

~Next, we set up a simple kinetic sorption study using a pump to easily obtain the precise results, and minimize artifacts. (Figure 2). In the pump method, drug solution (Figure 2a) was passed through a tube cut from the administration set (Figure 2b) after installation into an infusion pump (Figure 2c). Except for the tubes from administration sets, all devices (bottle, graduated cylinder, and sampling vials) were composed of chemically resistant borosilicate glass to prevent additional drug sorption to polymers.~

• *Step 4.2.1: The authors use diazepam stock solutions and standards for calibration that are made up in methanol, but are testing sample concentrations of diazepam made up in 5% dextrose. Please comment on the different solvents and what differences might be expected in HPLC chromatograms and/or quantitation of diazepam concentration. Author response: We already checked the diazepam concentration in samples using calibration curves from diazepam standards. Diazepam standards were insoluble in 5% dextrose, so they were dissolved in methanol and diluted with methanol. In samples, using a different solvent from standards, other interfering peaks may be presented in the chromatograms. In this case, although there are peaks at 4 - 6 min before diazepam peak, they were not overlapped to*

diazepam peak in the chromatogram. Please discuss your response in the Results or Discussion section.

→We added the response in results.

#### **REPRESENTATIVE RESULTS**

~ Analysis conditions are listed in Table 1. For the preparation of drug standards, diazepam and tacrolimus were dissolved in methanol and acetonitrile because of their insolubility in 5% dextrose. ~ There were no interfering peaks from the matrix. Specifically in samples of diazepam sorption study, the interfering peaks were not overlapped to drug peak in the chromatogram although the different solvent (5% dextrose) was used from standards.~